The Role of Genetic Polymorphisms in the Chemokine and their Receptors and Cytokines in the Human Immunodeficiency Virus Type 1 (HIV-1) Infection by Edna Maria Vissoci Reiche et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
12 
The Role of Genetic Polymorphisms in the 
Chemokine and Their Receptors and Cytokines 
in the Human Immunodeficiency Virus Type 1 
(HIV-1) Infection 
Edna Maria Vissoci Reiche, Marla Karine Amarante and  
Maria Angelica Ehara Watanabe   
State University of Londrina 
Brazil 
1. Introduction  
The natural history and pathogenic processes of human immunodeficiency virus type 1 (HIV-
1) infection are complex and variable, and depend on many viral and host factors and their 
interactions (Pantaleo et al., 1997). Individuals are not equal susceptible to the infection and 
have differences in their viral set points, rates of decline of CD4+ T cells, levels of viremia, 
emergence of citotoxic T lymphocyte (CTL) escape mutants, and development of opportunistic 
infections resulting in varying incubation periods of the virus (Kaur & Mehra, 2009). HIV-1 
infected individuals present different rates of disease progression; while a majority of 
individual progress to acquired immunodeficiency syndrome (AIDS) after the infection, most 
of them can be turned aviremic even the absence of antiretroviral therapy (ARV) up to ten 
years and are called typical progressors. Most importantly, ~5% to 10% of persistently infected 
individuals show no signs of disease progression for over 12 years and remain asymptomatic 
and aviremic and are classified as long term nonprogressors (LTNPs). On the other hand, 
rapid progressors are individuals that rapidly progress to AIDS within four years after 
primary HIV-1 infection and some individuals have been known to progress to AIDS and 
death within a year after primary infection (Fauci et al., 1996; Rosenberg & Fauci, 1991).  
Genetic factors may be one of the host factors responsible for the susceptibility to infection 
and disease progression. However, no single gene or polymorphism is likely to be 
responsible for these effects. Brass et al. (2008) have reported that HIV-1 uses at least 250 
host-derived dependency factors for gaining entry into target cells and completing its life 
cycle. Hence, multiple genetic factors are expected to be involved in susceptibility, disease 
pathogenesis, and progression following HIV-1 infection. Some of these genes that have 
been established with HIV/AIDS conclusively involve are: (1) genes influencing viral entry 
by altering the expression on cell surface the levels of chemokine receptors and their ligands 
as well cytokines (Seisdedos & Parmentier, 2006; Reiche et al., 2007); (2) genes involved in 
anti-HIV immune response including the antiviral Apolipoprotein B mRNA-editing 
enzyme, catalytic polypeptide-like 3G (APOBEC3G) gene family on chromosome 22q13 (An 
et al., 2009); the virus restriction factor Tripartite Interaction Motif 5  (TRIM5) on 
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chromosome 11p15; (3) the human leukocyte antigens (HLA) polymorphic loci and their 
associated genes including HCP5, RNF39, and ZNRD1 on the short arm of human 
chromosome 6; (4) Dendritic Cell Specific Intracellular adhesion molecule-3-Grabbing Non-
integrin (DC-SIGN) on chromosome 19q13; (5) interferon regulatory factor 1; (6) killer cell 
immunoglobulin-like receptor (KIR) KIR3DSI on chromosome 19q13; and (7) Ly6 family of 
G [glycosylphosphatidylinositol (GPI)-anchored proteins] (Kaur & Mehra, 2009).  
This chapter reviews the most important genetic polymorphisms already described in 
the chemokine, cytokine and their receptors, and their role on the host susceptibility or 
resistance to HIV-1 infection, on the clinical course of the disease and on the response to 
the ARV. For this purpose, in vitro and in vivo studies for inclusion were identified by a 
systematic search through PubMed for English-language literature, included original 
and review articles published up to 2010. These data could contribute to identify some 
genetic biomarkers for infection, transmission, disease progression or ARV therapeutic 
failure.  
2. Genetic polymorphisms in CC chemokines and their receptors 
Chemokines are low-molecular-weight potent chemoattractants produced by a variety of 
cell types that include T cells, macrophages, natural killer (NK) cells, B cells, fibroblasts, and 
mast cells. These are involved in cell trafficking and immunomodulation of inflammation 
and immune responses. The chemokines are subdivided into CC, CXC, and CX3C 
subfamilies, according to the number of cysteine residues in the molecule. Members of CC 
chemokines are CCL3 [macrophage inflammatory protein-1 (MIP-1)], CCL4 [macrophage 
inflammatory protein 1β (MIP-1)], and CCL5 [regulated upon activation normally T-
expressed (RANTES)]. They are natural ligands for CC chemokine receptor R 5 (CCR5). One 
member of CXC chemokines is CXC ligand 12 (CXCL12), previously named stromal cell-
derived factor 1 (SDF1), a natural ligand for CXC receptor 4 (CXCR4). In certain instances, 
the chemokine receptors serve as entry portals for pathogens to gain entry into target cells 
and establish infection. Based on cell tropism, HIV-1 isolates are classified into two main 
groups. The vast majority of primary HIV-1 isolates is, predominantly, tropic for CCR5 and 
gradually tends to become CXCR4 tropic during late infection. All non-syncytium-inducing 
(NSI) strains of HIV-1 require CCR5 to gain entry into target cells and are also named R5 
strains, while the syncytium-inducing (SI) strains use CXCR4 to enter into host cells and are 
also named as X4 strains (Berger et al., 1999). Functional genetic polymorphisms are known 
to occur in these proteins that affect their levels of expression and therefore might modulate 
their molecular interactions.    
2.1 CCL3, CCL4 and CCL18 
The genes coding for CCL3 (MIP-1), CCL4 (MIP-1), and CCL18 [also referred to as small 
inducible cytokine subfamily A member 18 or pulmonary and activation-regulated 
chemokine (PARC)], are clustered together within a 47-kb region on chromosome 17q12. 
These are potent chemokines produced by macrophages, NK cells, fibroblasts, and T cells. 
Of these, CCL2, CCL3 and CCL4 are natural ligands for the primary HIV-1 coreceptor 
CCR5, and their genetic polymorphisms have been implicated in HIV-1 acquisition and 
disease progression, although these associations are complicated because of strong linkage 
disequilibrium between them (Modi et al., 2006).  
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2.2 CCL5 
The CCL5 (RANTES) gene is located on chromosome 17 which encodes a chemokine 
ligand for CCR1, CCR3, and CCR5. It suppresses infection for R5 strains of HIV-1 by 
blocking CCR5 (Paxton et al., 1996; Arenzana-Seisdedos et al., 1996). Some 
polymorphisms in CCL5 promoter region protect HIV-1 infected subjects against disease 
progression as a result of increased CCL5 synthesis (Liu et al., 1999; Wichukchinda et al., 
2006). Three single nucleotide polymorphisms (SNPs) in this gene (-28CG, -403GA, 
and in 1.1C) were reported for their roles in progression to AIDS in HIV-1 infected 
individuals. The variant alleles -28G and -403A were found to be associated with delayed 
progression to AIDS in Japanese population by increasing levels of CCL5 transcription 
and by reducing rates of CD4+ T-cell depletion (Liu et al., 1999). Other study also 
suggested that polymorphisms in the CCL5 promoter gene can influence the risks for 
HIV-1 infection and disease progression by increasing the CCL5 levels (McDermott et al., 
2000; Koning et al., 2003). In the other hand, the SNP In 1.1C, nested within an intronic 
regulatory sequence element, accelerated the progression to AIDS in African Americans 
and European Americans by downregulating the CCL5 gene transcription (An et al., 
2002).  Study by Wichukchinda et al. (2006) demonstrated the mutation's protective effect 
by comparing disease progression in seroconverters carrying either the CCL5-28G or the 
CCL5 In.1.1C polymorphism. Individuals carrying the CCL5 In.1.1C allele progressed 
significantly faster to AIDS compared with those carrying the CCL5 - 28G allele, along 
with those HIV-1-infected subjects without these mutations. 
2.3 CCL3L1, CCL4L1 
Human CC chemokine ligand 3 like 1 gene (CCL3L1) is a natural ligand of HIV-1 coreceptor 
CCR5 and a potent HIV-1 supressive chemokine that can physically block the entry of HIV-
1. The CCL3L1 gene is located on human chromosome 17q11.2 and shares 96.0% amino acid 
homology with CCL3. The copy number of the CCL3L1 gene varies among different 
individuals and populations groups (Kaur & Mehra, 2009). CCL3L1 and CCL4L1 genes 
harbor several SNPs and hotspots for duplication, resulting in distinct haplotypes and copy 
number variations, respectively, in different individuals (Modi et al., 2006). The copy 
numbers are highest in Africans, followed by Asians, Amerindians Central and South 
Asians, Middle East individuals and Europeans.  Variations in a copy numbers of CCL3L1 
alter the expression of this potent CCR5 ligand and might influence the entry of HIV-1 into 
host cells. Copy number variations in CCL3L1 have been associated with susceptibility to 
HIV-1 infection (Gonzalez et al., 2005). However, the results are contradictory in different 
populations. A study carried out in the Japanese population (Nakajima et al., 2007) has 
shown that HIV-1 infected individuals have lower copy number than healthy controls. On 
the contrary, studies in North Indian population showed that the copy number variation in 
CCL3L1 gene has no effect on acquisition in HIV-1 infected individuals compared with 
healthy controls (Nakajima et al., 2008). Another study showed an association of CCR5-
59029 A/G and CCL3L1 copy number polymorphism with HIV-1 transmission and 
progression among HIV-1 seropositive and repeatedly sexually exposed HIV-1 seronegative 
North Indians individuals, suggesting that these polymorphisms appeared to have 
synergistic or interactive effects and are expected to be involved in the host innate resistance 
to HIV-1 infection  (Rathore et al., 2009).  
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2.4 CCR5  
CCR5 is normally expressed at very low levels on the surface of naïve CD4+ T cells and at 
higher levels in activated CD4+ memory T cells as well as in monocytes and macrophages 
(Potter et al., 2007). Multiple polymorphic variations have been described in the CCR5 gene 
that is located on chromosome 3p21. CCR5-32 polymorphism is the first and most well 
characterized host restriction allele associated with AIDS. This natural knockout deletion of 
32 base-pair creates a premature stop codon resulting in truncated protein product, a 
shortened protein which remains intracellular and fails to reach the cell surface in 
individuals homozygous for the variant. The first study described a frequency of 
approximately 0.100 for the null-mutant allele of the CCR5 gene in the Caucasian 
population. Heterozygotes for the allele have reduced levels of quantifiable CCR5 receptors 
in the cell surface and were present at similar frequencies among infected and uninfected 
cohort controls. Among HIV-1 infected homosexual cohorts, heterozygosity correlated well 
with decreased disease progression. However, no correlation was apparent among the 
haemophilic population (Dean et al., 1996). 
A second study identified the same mutant allele of CCR5 in two homozygous individuals 
who had been repeatedly exposed to the HIV-1 but remained uninfected (Liu et al., 1997). 
The results also showed that the mutation makes the CCR5 protein incapable of mediating 
infection by HIV-1 in vitro. A third study suggested that heterozygosity also provides some 
protection from HIV-1 infection (Samson et al., 1996) and the discrepancy regarding the 
protection from HIV-1 infection was most likely due to the difference between the 
populations evaluated. The first study (Dean et al., 1996) compared large and matched 
cohorts of individuals, whereas the third (Samson et al., 1996) examined only non-cohort 
population matched by geographical location and the use of a French surname. 
Even though homozygosity for the CCR5-32 results in near-total protection for the HIV-1 
infection, subjects can still be infected with T-tropic or SI strains of the virus, which use the 
CXCR4 coreceptor for cell entry (Dean et al., 1996; Samson et al., 1996; Zimmerman et al., 
1997; O’Brien et al., 1997; Theodorou et al., 1997). Studies of HIV-1 infected homozygous for 
the CCR5-32 mutation have been reported, but are rare (O’Brien et al., 1997; Theodorou et 
al., 1997; Balotta et al., 1997; Biti et al., 1997), probably due to a T-tropic virus, strain which 
only uses CXCR4 as coreceptor for cell entry. 
Heterozygosity for the CCR5-32 is significantly higher in cohorts of HIV-1 infected LTNPs 
compared to HIV-1 infected typical progressors (Cohen et al., 1997; Zimmerman et al., 1997; 
Eugen-Olsen et al., 1997). Although the heterozygosity was not related to the complete 
protection against HIV-1 infection (Dean et al., 1996; Samson et al., 1996), it may confer 
partial protection against disease progression or death in HIV-1 infected individuals 
(Zimmerman et al., 1997; Smith et al., 1997; Martin et al., 1998; de Roda et al., 1997; Meyer et 
al., 1999; Ionnadis et al., 1998). Presumably, heterozygosity limits the number of coreceptors 
available for HIV-1 binding. Indeed, CCR5 density of the surface of the CD4+ T cell has been 
correlated with viral load in persons with untreated HIV-1 infection (Reynes et al., 2000). 
Studies incorporating viral phenotype have suggested that the protective effect of CCR5-32 
heterozygosity against disease progression is lost when the infection virus is T-tropic 
(Michael et al., 1997). 
An international meta-analysis showed that HIV-1 infected subjects heterozygous for the 
CCR5-32 displayed lower HIV-1 RNA level than wild type patients. This result appears to 
be supported by the simple explanation that the fewer available CCR5 portals on cells of 
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CCR5-32 delay HIV-1 replication and the virus-mediated destruction of the CD4+/ CCR5+ 
T-cell lymphocyte population (Ioannidis et al., 2001). The observation that this naturally-
occurring genetic mutation can slow or delay the onset of AIDS in patient populations was 
the basis of therapeutic interventions targeting the interaction between the virus and the 
coreceptor CCR5.  
Several other mutations in the coding region of the CCR5 gene have been identified 
(Carrington et al., 1997). Ten common SNPs within the 1,000 base-pairs region upstream of 
CCR5-coding exons that exhibit promoter and regulatory activity have been described, 
possibly affecting the levels of CCR5 expression (Carrington et al., 1999; Martin et al., 1998; 
Kostrikis et al., 1998; Quillent et al., 1998; Piacentini et al., 2009). These polymorphisms are 
identified as CCR5P1 to CCR5P10 and the most common of them  are CCR5P1 and CCR5P4 
(Chatterjee, 2010).    
The CCR5P1/P1 promoter allele was the first genetic variant in the CCR5 promoter to be 
associated with rapid progression of AIDS, although variants of other genes have been 
described more recently to be AIDS-accelerating (Carrington et al., 1997; Faure et al., 2000). 
The hypothesis that the genetic effect is mediated by an increase in available CCR5 portals is 
also supported by the epidemiologic pattern. The strongest acceleration mediated by the 
CCR5P1/P1 genotype occurs in the first five years of infection, a period when R5 (NSI) virus 
strains predominate in 90.0-95.0% of patients (Schuitemaker et al., 1992). 
The A/G polymorphism at base-pair 59029 in the CCR5 promoter was identified and 
appears to affect the rate of progression to AIDS in HIV-1 infected homosexuals. The CCR5 
59029 G/G genotype appears to be more protective than CCR5 59029 A/A, and this effect 
may be the result of a reduced CCR5 mRNA production. The A allele exhibits a 50.0% 
higher expression of CCR5 in vitro and confers faster disease progression than the G allele 
(Passam et al., 1999). These results indicated that this site in the CCR5 promoter is important 
and may be a useful target for treatment of the HIV-1 infection (McDermott et al., 1998). 
It is estimated that homozygozity for the CCR5P1/P1 promoter allele was responsible for 
the development of the disease in 10.0% to 17.0% of the patients who developed AIDS 
within 3.5 years of HIV-1 infection, irrespective of the CCR5-32 and CCR2-64I (defined in 
this chapter in the next sections) genotypes. The frequency of this susceptible genotype in 
the general population is only 7.0% to 13.0% (Martin et al., 1998). 
Homozygosity for CCR5-59356-T, a polymorphism more frequent in the African-American 
rather than in Caucasian or Hispanic populations, has been strongly associated with an 
increased rate of perinatal HIV-1 transmission (Kostrikis et al., 1999). Additionally, the 
59353C allele is found in higher frequency in some progressors compared with LTNPs (Jang 
et al., 2008).  
Complete linkage disequilibrium between CCR5P1 and CCR5-2459A sites and the CCR5P1 
haplotype was shown to be associated with rapid progression to AIDS endpoints in both 
African-American and Caucasians cohorts. This effect was recessive in Caucasians and 
dominant in African-Americans, probably due to the presence of modulating genes or as yet 
unidentified polymorphisms with different frequencies among the racial groups (An et al., 
2000). This same study described that both CCR5P1 homozygous and heterozygous African-
Americans showed a trend towards more rapid progression to AIDS endpoints. Similar to 
the recessive effect of the CCR5P1 allele in Caucasians, which was strongest in the first 4-6 
years following seroconversion, the dominant effect of the CCR5P1 allele in African-
Americans was also evident in the first 4 years. This result is consistent with both the 
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function of CCR5 as the coreceptor for early transmissible M-tropic HIV-1 strains and also 
with the studies of CCR5-32 showing an early effect (Dean et al., 1996). 
Unlikely the CCR5-32 mutation which is found only in people of Northern European 
descent, the CCR5P1 allele has a frequency larger than 40.0% both in Caucasians, Asians and 
populations of African descent, suggesting that the CCR5P1 allele may have a more general 
effect on AIDS pathogenesis worldwide (An et al., 2000). 
Another SNP in CCR5 gene is a TA substitution (named CCR5-m303A polymorphism) 
and results in a Threonine to Alanine transition at position 303. It encodes a truncated 
protein and abolishes the coreceptor activity of CCR5. This polymorphism shows a weak 
association with delayed progression to AIDS. When is present in heterozygous state with 
CCR5-32, produces a phenotype of resistance to HIV-1 in primary isolates in vitro (Quillent 
et al., 1998). 
Based on a unique constellation of additional multisite polymorphisms in CCR5 regulatory 
5’ region, a number of CCR5 haplotypes have been identified (Gonzalez et al.,1999; Martin et 
al., 1998). They have been designed based on the nucleotide position in the 5’ untranslated 
region (UTR) and are referred to as human haplogroups A to G. Of these, HHE has been 
associated with accelerated disease progression in Caucasians (Gonzalez et al., 1999) and 
Thais (Nguyen et al., 2004) but not in African Americans. The HHC and HHD haplotypes 
showed positive association with fast progression to AIDS in African Americans (Kostrikis 
et al., 1999; Nguyen et al., 2004). In the Indian population, HHE has been implicated with 
susceptibility to infection and development of AIDS (Kaur et al., 2007). Whether this 
haplotype also influences disease progression is not clear because long-term follow-up is 
desirable to reach such a conclusion (Kaur & Mehra, 2009).      
2.5 CCR2  
Although the HIV-1 virus does not directly use CCR2 for host cell entry, and CCR2 is 
considered a minor coreceptor for HIV-1 infection, a Valine to Isoleucine substitution at 
position 64 in the first transmembrane domain of CCR2 (named CCR2-64I, V64I or G190A) 
has been associated with delayed progression to AIDS (Smith et al., 1997). HIV-1 infected 
individuals heterozygous or homozygous for this mutation appear to progress to AIDS or 
death more slowly. However, this mutation results in normal levels of expression of the 
CCR2 receptor and has not been shown to affect the susceptibility to HIV-1 infection (Smith 
et al., 1997; Martin et al., 1998; de Roda et al., 1997; Kostrikis et al., 1998; Mummidi et al., 
1998; Mulherin et al., 2003). 
Even though the change of the Valine to Isoleucine in a position buried in one of the seven 
transmembrane segments of this receptor could be considered innocuous, the 
epidemiological effect on AIDS progression was surprising. It has been shown that the 
CCR2-64I protein product can preferentially dimerizes with the CXCR4 polypeptide, 
sequestering it in the endoplasmic reticulum, while the CCR2 peptides cannot. Such 
differential intracellular kinetics between CCR2 allele products and primary HIV-1 
coreceptors in vivo could reduce the rate of disease progression by limiting the number of 
available CXCR4 coreceptors, therefore also reducing indirectly the rate of viral replication 
(O’Brien and Moore, 2000). However, this effect on disease progression has not confirmed 
(Michael et al., 1997; Eugen-Olsen et al., 1998). 
The distribution of CCR2-64I varies among different ethnic groups. Unlike the CCR5-32 
mutation, which is found primarily in Caucasians, the frequency of the CCR2-64I allele 
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varies from 10.0% to 25.0% in both African-Americans and Caucasians, and in all other 
ethnic groups studied. The protective allele A occurs at a population frequency of  
15.0%-17.0% in Chinese, 12.0% in the North Indians (Kaur et al., 2007), and 3.0%-15.0% in 
the South Indian populations (Ramana et al., 2001). Studies of HIV-1 infected commercial 
sex workers in Nairobi and Kenya, suggested that the presence of the mutation helped to 
explain slow progression in 21.0% to 46.0% of slow progressors (Anzala et al., 1998). The 
effect of the CCR5-32 allele on HIV-1 disease progression was also different from the effect 
of the CCR2 allele. The protection against AIDS provided by CCR5-32 was continuous 
during the course of infection, while the protection provided by CCR2-64I was the greatest 
early in the course of infection (Mulherin et al., 2003). 
A meta-analysis study found that in the absence of highly active antiretroviral therapy 
(HAART), both CCR5-32 and CCR2-64I carriers progressed to AIDS at a 25.0% slower rate 
than individuals who lacked either of these protective alleles. They also progressed more 
slowly to death, approximately 35.0% and 25.0% slower, respectively (Ioannidis et al., 2001). 
Mabuka et al. (2009) verified that the presence of the CCR2-64I allele was associated with 
reduced viral load and with protection against early HIV-1 transmission among pregnant 
women who received short course zidovudine. In Kenya and other African countries, where 
approximately one quarter of individuals carry the variant allele, understanding this genetic 
mutation may help explain disparities in transmission risk and rates of disease progression 
and could contribute to vaccine development and other prevention interventions. 
Because the genetic loci for CCR5 and CCR2 are in strong linkage disequilibrium, their 
combined analysis is greatly helpful to define CCR2-CCR5 extended haplotypes for disease 
association purposes (Kaur & Mehra, 2009). 
3. Genetic polymorphisms in CXC chemokines and their receptors 
3.1 CXCL12 (SDF1)  
CXCL12 (SDF1) is a highly potent  chemokine, the natural ligand for the CXCR4, and a 
potent entry inhibitor for T-tropic (X4 or SI) HIV-1 strains that generally emerge during the 
late-stage of HIV-1 infection (Bleul et al., 1996). The CXCL12-CXCR4 interactions are 
essential for the homing and retention of hematopoietic progenitor cells in the bone marrow 
and have been shown to control the navigation of progenitor cells between the bone marrow 
and the blood. The gene for CXCL12 (SDF1) is ~10kb long and located on human 
chromosome 10q11.1. It exists in two isoforms,  and β, obtained as a consequence of 
alterative splicing. A common G to A transition, initially referred to as SDF1-3’A and 
currently named CXCL12-3’A, was described at an evolutionarily conserved sequence of the 
3’UTR of the β transcript gene. The polymorphism at the 801 position (G801A or CXCL12’A) 
has been shown to have a recessive protective effect against HIV-1 infection. Homozygotes 
for the CXCL12-3’A variant showed a remarkable level of protection against AIDS, 
supporting the hypothesis that the CXCL12-3’A variant restricts the emergency of X4 HIV-1 
strains, with overproduction of CXCL12 in local compartments, which binds to and blocks 
the CXCR4 receptors required for X4 viruses to emerge and multiply (Winkler et al., 1998). 
However, direct evidence for an effect of CXCL12-3’A on the synthesis, quantity or half life 
of the ligand has not been obtained in vitro (Arya et al., 1999). Because CXCL12 expression is 
limited to stromal cells and other tissues that are not easy to quantify, this hypothesis is 
difficult to test in vivo (Bleul et al., 1996). 
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Global, regional, and ethnic distributions of frequencies of CXCL12 genotypes and of the 
CXCL12-3’A allele vary significantly, ranging from 0.029-0.091 in Africans, 0.056-0.150 in 
American Indians, 0.149-0.217 in Europeans, 0.09- 0.380 in North Asians, 0.06-0.43 in South 
Asians, and 0.536- 0.7145 in Oceanian population (Su et al., 1999). In other ethnic cohorts, the 
allelic frequency of CXCL12-3’A ranged from 0.100 to 0.332 (Passam et al., 2005; Williamson 
et al., 2000; Wang et al., 2003). The frequency of the CXCL12 polymorphisms was also 
investigated in various cohorts of HIV-1 exposed but uninfected and among HIV-1 infected 
individuals. The results showed that the CXCL12-3’A allele delayed progression to AIDS 
but not decreased the susceptibility to HIV-1 infection (Winkler et al., 1998). Another study 
showed that the CXCL12-3’A homozygous mutation did not influence the clinical course of 
asymptomatic patients. However, the lower number of deaths during the follow-up period 
among symptomatic patients who were homozygotes and heterozygotes for the CXCL12-
3’A allele, suggested that both genotypes could have a possible late-stage protective effect 
on the clinical outcome of HIV-1 patients after the AIDS diagnosis (Reiche et al., 2006). 
However, the disease-retarding role of homozygosity for the CXCL12-3’A allele has not 
been confirmed in other cohorts (Mummidi et al., 1998; Wang et al., 2003; van Rij et al., 1998; 
Magierowska et al., 1999; Rousset et al., 1999; Brambilla et al., 2000; Soriano et al., 2002).  
Verma et al. (2007) observed a low frequency of CCR5-Δ32 (1.5%) and of CCR2-64I (9.1%) in 
healthy Northern Indians, suggesting high vulnerability of North Indians to HIV-1 infection. 
However, the allelic frequency of the CXCL12 3’A was high (20.4%) in the healthy HIV-1 
seronegative Northern Indians included in their study, which was similar to that observed 
in South Indians (17.0%–35.0%) and South European populations (14.0%–33.0%) (Ramana et 
al., 2001).  
Chaudhary et al. (2008) examined the SNP of CXCL12 3’A by polymerase chain reaction- 
restriction fragment length polymorphism (PCR-RFLP), cloning and sequencing in 
individuals from Northen India and showed that the genotypic frequency of CXCL12 
3’A/CXCL12 3’A in the 100 HIV-1 seronegative healthy individuals, in 150 HIV-1 
seronegative individuals with high risk for sexually transmitted disease (STD), and in 100 
HIV-1 seropositive patients were 4.0%, 18.0% and 7.0%, respectively. A significantly higher 
frequency of  CXCL12 3’A/CXCL12 3’A was observed in high risk STD individuals as 
compared to HIV-1 seropositive (p = 0.014) and  healthy HIV-1 seronegative tested 
individuals (p = 0.001), suggesting a protective role of CXCL12 3’A allele in HIV-1 infection. 
In this study it was observed a significant increase in the homozygous genotype for the 
mutant allele CXCL12 3’A in the high risk STD individuals as compared to both the healthy 
seronegative and HIV-1 seropositive individuals, suggesting a possible protective role of 
this allele in the homozygous state against HIV-1 infection. 
The frequencies of CXCL12 3’A, CCR5-32, CCR5-m3030, and CCR2-64I allelic variants 
were investigated in unrelated healthy Bahraini individuals without any known history of 
HIV-1 infection or AIDS symptoms. The results showed that CCR2-64I allele (8.9%) and 
especially the CXCL12 3’A allele (26.5%) were predominant and may be associated with 
resistance to fast HIV-1 infection in this population, and thus their genotyping could be 
used for prognosis in HIV-1 infected individuals. No mutant alleles were detected for CCR5-
m303A mutation and the frequency of 2.8% for CCR5-32 allele may be attributed to the 
admixture with people of European descent (Salem et al., 2009). 
The epidemiological interaction of CCR5/CCR2 and CXCL12-3’A suggests that a functional 
interaction might explain the enhanced protection. One hypothesis is that CCR2 and CCR5 
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variants slow AIDS by limiting the number of CCR5 coreceptors that mediate the replication 
and spread of primary, early stage R5 HIV-1 strains, while the CXCL12-3’A variant restricts 
the emergence of X4 HIV-1 strains and the ensuing AIDS-accelerating process (O’Brien and 
Moore, 2000). 
However, several studies show a lack of relationship between CXCL12 3’A and HIV-1 
disease non-progression (Vidal et al., 2005a; Ioannidis et al., 2001; Tresoldi et al., 2002). For 
instance, in their international meta-analysis, Ioannidis et al. (2001) measured the effects of 
subjects homozygous for the CXCL12 3’A polymorphism by reviewing studies that 
prospectively followed HIV-1 infected patients from seroconversion to AIDS diagnosis and 
death. Results showed that being homozygous for the polymorphism had no effect on 
disease progression and there was no significant difference in HIV-1 RNA levels among 
persons with and without the polymorphism. 
Recently, Tan et al. (2010) showed that the allelic frequency of CCR5-32, CCR5m303A, CCR2-
64I and CXCL12-3’A in HIV-1 infected and uninfected high-risk Uighurs individuals, the 
largest population of minority in China, was 4.4%, 2.7%, 25.7% and 57.4%, respectively. While 
there was no significant difference in the frequency of CCR5-32, CCR2-64I and CXCL12-3’A 
between HIV-1 seropositive and seronegative group, the frequency of CCR5m3030A in HIV-1 
seropositive group was significantly higher than that in seronegative group. Furthermore, a 
woman who carried homozygous CCR5-32 was positive for HIV-1 infection. Therefore, these 
data suggest that the CCR5-32 CCR2-64I and CXCL1´3’A alleles may have limited effect on 
protecting from HIV-1 infection and CCR5m303A variant may be associated with the risk for 
HIV-1 infection in high-risk Uighurs individuals.  
The distribution of CCR5-32, CCR2-64I, and CXCL12 3’A alleles was evaluated in Guangxi 
Province Zhuang population, the largest minority ethnic population with over 15 million 
people, mainly located in Guangxi Province, China. The CCR5-32 was absent, and CCR2-
64I and CXCL12 3’A alleles were relatively common and seem not to confer protection 
against HIV-1 infection in this population. The results suggest that the Zhuang people may 
have a similar genetic susceptibility to HIV-1 infection with most other Chinese ethnic 
groups (Qijian et al., 2010). 
3.2 CXCR1, CXCR2 
CXCR1 (IL-8RA) and CXCR2 (IL-8RB) are receptors for IL-8, a proinflammatory cytokine 
involved in chemoattraction and activation of neutrophils. CXCR1 and CXCR2 genes are 
located o chromosome 2q35 and several polymorphisms have been described including 
SNPs T92G (CXCR1 -300) and C1003T (CXCR1-142) that result in a CXCR1 haplotype Ha. A 
genetic study on French cohort composing of rapid and slow progressors HIV-1 infected 
individual identified a strong association of CXCR1 haplotype Ha with protection against 
rapid progression to AIDS (Vasilescu et al., 2007).  It was suggested that the inhibitory effect 
of CXCR1 Ha could be mediated by suppressing CD4+ and CXCR4 expression (Kaur & 
Mehra, 2009).   
3.3 CXCR4  
The highly conserved CXCR4 gene is an obvious target as CXCR4 serves a coreceptor for X4 
(SI) strains of HIV-1 to gain entry into cells. This gene is located on chromosome 2 and the 
screening of entire transcription unit resulted in the detection of two rare polymorphisms. 
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One of these CXCR4 mutations was silent, and each was unique to two nonprogressors. 
However, no association with progression to AIDS was found (Cohen et al., 1998).   
3.4 CXCR6 
The CXCR6 is a chemokine receptor that is known as a minor coreceptor in HIV-1 infection 
but could participate in disease progression through its role as a mediator of inflammation.   
Petit et al. (2008) described the effects of mutation of acidic extracellular CXCR6 residues on 
receptor function. Although most CXCR6 mutants examined were expressed at levels 
similar to wild-type CXCR6, the N-terminal E3Q mutant was poorly expressed, which may 
explain previously reported protective effects of a similar SNP, with respect to late-stage 
HIV-1 infection. In contrast to several other chemokine receptors, mutation of the CXCR6 N-
terminal and inhibition of post-translational modifications of this region were without effect 
on receptor function. This data suggests a novel paradigm for the CXCR6:CXCL16 
interaction, a finding which may impact the discovery of small-molecule antagonists of 
CXCR6. 
Study by Limou et al. (2010) verified that the rs2234358 polymorphism in the CXCR6 gene 
was the strongest signal obtained for the genomewide association study comparing the 186 
Genomics of Resistance to Immunodeficiency Virus (GRIV) LTNPs who were not elite 
controlls with 697 uninfected control subjects. This association was replicated in 3 additional 
independent European studies, reaching genomewide significance. This association with 
LTNPs is independent of the CCR2-CCR5 loci and the HCP5 polymorphisms. The statistical 
significance, the replication, and the magnitude of the association demonstrate that CXCR6 
is likely involved in the molecular etiology of AIDS and, in particular, in LTNPs, 
emphasizing the power of extreme-phenotype cohorts.  
4. Genetic polymorphisms in CX3C Chemokine Receptor (CX3CR) 
4.1 CX3CR1  
CX3CR1, a leukocyte chemotactic and adhesion receptor for the human chemokine 
fractalkine, has also been defined as a minor HIV-1 coreceptor, particularly expressed on 
brain. Mutations on the CX3CR1 gene, located at chromosome 3, have been described, such 
as V249I (substitution changed Valine to Isoleucine) and T280M (substitution changed 
Threonine to Methionine) (Faure et al., 2000), with frequency of 26.0% and 13.0%, 
respectively. The impact of CX3CR1 polymorphisms on HIV-1 pathogenesis is controversial, 
with conflicting reports of their role in disease progression in HIV-1 infected patients. 
Individuals homozygous for the 280M allele exhibited accelerated disease progression 
(Faure et al., 2000, 2003), with a small but statistically significant correlation with slightly 
earlier immunological and virologic failure (Brumme et al., 2003). However, further studies 
did not confirm this observation (McDermott et al., 2000; Kwa et al., 2003).  
Polymorphisms in CCR2 and CX3CR1, which HIV-1 sometimes uses as coreceptors, have 
also been associated with slowing HIV-1 disease progression. For example, the CCR2-64I 
mutation has been shown to reduce CXCR4 expression on CD4+ T cells, thereby interfering 
with X4-tropic virus infection (Kalinkovich et al., 1999). In one study's cohort of HIV-1 
positive Kenyan sex workers (Anzala et al., 1998), the frequency of being positive for CCR2-
64I was highest in LTNPs, which was three times greater than that for progressors. In a 
separate study, Vidal et al. (2005b) found that the CX3CR1 V249I polymorphism is 
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significantly  more frequent in LTNPs than progressors, but not than healthy controls. It has 
been observed that there was a large discrepancy between these alleles among populations 
of the north and south. Populations in the same language-speaking family or with the same 
origin shared similar allele distributions. 
Puissant et al. (2006) observed that some genetic polymorphisms had an impact on the 
evolution of plasma virus load and peripheral T lymphocyte counts in HIV-1 infected 
patients under HAART. After 1 year of HAART, patients with a virological response 
(undetectable plasma HIV-1 RNA) have a higher frequency of the homozygous CXCL12 3’A 
genotype than patients with other polymorphisms such as CCR5-32, CCR2-64I, CX3CR1-
249I, and CX3CR1-280M. Similarly, patients with a CD4+ T cell increase of over 200/mm3 
from baseline after 1 year of HAART display higher frequencies of homozygous CXCL12 
3’A and homozygous CX3CR1-280M genotypes than other patients. Moreover, the authors 
showed that CX3CR1-280M allele was associated with high peripheral CD4+ T cell counts 
not only in HIV-1 soropositive patients but also in healthy controls.      
Qian et al. (2008) showed that the frequencies of CX3CR1-249I and 280M alleles varied 
substantially among different population and were independent risk factors for accelerating 
the progression to AIDS. Further, Parczewski et al. (2009) studied the influence of genetic 
variants for CCR5-32, CCR5 -G2459A, CCR2- G190A, CX3CR1- G744A, and CX3CR1- 
C838T in a cohort of 168 HIV-1 seropositive adults and 151 healthy newborns from 
northwestern Poland. The results showed that haplotypes containing CCR5-32, CCR2- 
G190A, and CX3CR1- G744A were significantly more common in the healthy newborns 
suggesting an association between these haplotypes and resistance to HIV-1 infection in this 
population.   
5. Genetic polymorphism in cytokines and their receptors 
Like chemokines, the role of cytokines in the modulation of HIV-1 infection and the rate of 
disease progression remains to be fully understood. Evidence of strong epidemiological 
associations between cytokines and HIV-1 disease progression has been limited and, in 
some cases, inconsistent across studies. Studies have shown that cytokines can have 
inhibitory, stimulatory or both effects on HIV-1 replication (Han et al., 1996; Naif et al., 
1997).  
5.1 Interleukin-4 (IL-4) and IL-4 Receptor (IL-4R) 
IL-4 is an important cytokine that induces differentiation of CD4+ Th cells. It also 
regulates the expression of the HIV-1 coreceptors CCR5 and CXCR4. IL-4 decreases the 
levels of CCR5 on the surfaces of CD4-bearing cells and increases CXCR4 levels on the 
same or other cells. IL-4 gene is located on chromosome 11 and a SNP in the regulatory 
region of IL-4 gene (IL4-589 C/T), initially identified among HIV-1 seropositive Japanese 
individuals, has been reported to have a protective effect against transmission of HIV-1 
through heterosexual contact.  The IL4-R alpha I50V polymorphism in exon 5 of IL-4R 
gene affects the functional responsiveness of the gene (Risma et al., 2002). The SNP I50V 
was found to be associated with slow progression to AIDS in HIV-1 infected individuals 
(Soriano et al., 2005). However, another study suggested an association of IL-4R alpha 
I50V allele with increased likelihood of HIV-1 infection in North Indian population 
(Chatterjee et al., 2009).   
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5.2 Interleukin 10 (IL-10)  
The interleukin-10 (IL-10) is known to inhibit HIV-1 replication in macrophages in vivo 
(Kollmann et al., 1996). The gene encoding IL-10 is situated on chromosome 1 and a 
polymorphism with CA transition in the promoter region at position -592, named IL10-
C592A, has been associated with diminished IL-10 production and accelerated progression 
to AIDS with a dominant effect (Winkler et al., 1998). This SNP is carried by 23.6% of the 
Caucasians, 40.0% of the African Americans, 33.0% of Hispanics, and 60.0% of the Asians. 
The molecular mechanism behind this SNP is not well understood but is has been predicted 
that IL-10 may control proliferation of HIV-1 by limiting the number of activated 
macrophages available for HIV-1 replication (Chatterjee, 2010).      
5.3 Tumor Necrosis Factor Alpha (TNF-) 
TNF- is a pro-inflammatory cytokine and is known to be involved in the various 
immunogenetic events that influence HIV-1 infection. The gene encoding TNF- is located 
on chromosome 6 and four polymorphisms in the TNF- promoter have been identified, all 
with GA transitions; however, the information available of how TNF- genetic variants 
affect vulnerability to HIV-1 infection is inconsistent (reviewed by Chatterjee, 2010). Veloso 
et al. (2010) determined whether carriage of the TNF- -238G/A, -308G/A, and -863 C/A 
gene promoter SNPs influence the risk of HIV-1 infection and disease progression in 
Caucasian Spaniards. For this purpose, 239 heavily exposed but uninfected individuals 
(EU), 203 healthy controls (HC), 109 HIV-1 infected typical progressors (TP) and 75 HIV-1 
infected LTNPs were evaluated. The results showed that the distribution of TNF- variants 
did not differ among HIV-1 infected compared with EU and among TP and LTNPs. The 
analysis in LTNPs subset indicated that TNF--238A variant allele was significantly 
overrepresented in patients who spontaneously controlled plasma viremia compared with 
those who had a detectable plasma viral load. Taken together, the results suggested that 
TNF- genetic variants were unrelated to disease progression in infected subjects but the -
238 G/A SNP may modulate the control of viremia in LTNPs.      
5.4 Interferon alpha receptor 1 (IFNAR1) 
Interferon alpha (IFN-) elicits a pleotropic antiviral response and form the first line of 
defense against HIV-1 infection. This cytokine acts through the IFN- receptor (IFNAR) that 
is composed of two subunits, IFNAR1 and IFNAR2, encoded by the gene located at 
chromosome 21q (Kim et al., 1997). Two SNPs in the IFNAR1 gene, IFNAR1-18339GC 
(Valine to Leucine change in exon) and IFNAR1-30127CT (in intron), found in tight 
linkage disequilibrium were associated with susceptibility to HIV-1 infection (Diop et al., 
2006).        
6. Genetic polymorphism and the response to antiretroviral therapy 
The observations that genetic markers influence the natural history of HIV-1 and that the 
infection and the immunological and virologic responses to HAART is neither universal nor 
homogeneous (DeHovitz et al., 2000), lead to the thought that the response to treatment may 
also be genetically determined. Polymorphisms in the chemokine and chemokine receptor 
genes may affect response to HAART, in addition to other host factors governing poor 
immune response to HAART, such as increasing age (Viard et al., 2001), injection drug use 
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(Dronda et al., 2002), hepatitis C virus coinfection (Greub et al., 2000), and lower baseline 
CD4+ T cell count (Vaamonde et al., 2006). 
Genetic polymorphisms could also explain the heterogeneity in sustaining viral suppression 
observed among patients receiving HAART (O’Brien et al., 2000). Approximately 10.0% of 
HIV-1 infected patients do not respond to HAART with a reduction of viral load, even if 
there is good compliance and no evidence of viral resistance (Lederberger et al., 1999). 
However, studies investigating the association between genetic polymorphisms and 
response to HAART have provided conflicting data. An improvement in the immunological 
and the virological responses in association with the CCR5-32, CCR2-64I, CXCL12-3’A, and 
CCR5-59029G/A polymorphisms has been reported (O’Brien et al., 2000; Guerin et al., 2000; 
Kasten et al., 2000; Yamashita et al., 2001). HIV-1 infected patients with wild type genotypes 
for the CCR5, CCR2, and 59029A alleles treated with HAART had the poorest response to 
therapy compared with patients with other genotypes combined with the CCR5-32, CCR-
64I or 59029G alleles (O’Brien et al., 2000). Polymorphism within the CX3CR1 gene was 
associated with accelerated virological and immunological therapy failure (Brumme et al., 
2003). One report (Puissant et al., 2006) showed that, after one year of HAART, patients with 
undetectable plasma HIV-1 RNA levels have a higher frequency of the homozygous 
CXCL12-3’A genotype than other patients. Similarly, patients with a CD4+T cell count 
increase of over 200/mm3 from baseline after one year of HAART display higher 
frequencies of homozygous CXCL12-3’A and CX3CR1-280M genotypes than other patients. 
Another study that evaluated a subgroup of patients with baseline CD4+ T cell count of 201-
500 cells/mm3, showed that both the CXCL12-3’A and CCR2-64I alleles displayed a positive 
influence on clinical progression after HAART initiation. The CXCL12-3’A allele showed 
this effect through a more rapid CD4+ T lymphocyte restoration counts above the level of 
500 cells/mm3, while CCR2-64I was associated with stronger viral suppression. Regarding 
the CCR5-32 and CCR5-59029G/A alleles, they had no effects on the response to HAART 
initiation (Passam et al., 2005). In contrast, other studies did not find such correlation 
(Brumme et al., 2001; Bratt et al., 1998; Wit et al., 2002). However, one of these studies (Bratt 
et al., 1998) did not exclude nonadherent patients, and analyzed their data on an intent-to-
treat basis, thus reducing the likelihood of finding a difference. In addition, 69.0% of their 
CCR5/32 heterozygous patients had SI virus isolates, and therefore, tended to have lower 
CD4+ T cell counts, higher plasma HIV-1 RNA levels, and a greater proportion of 
azidothymidine resistance mutations. 
Another study evaluated the CCR5-32, CXCL12-3’A, and CCR2-64I genetic polymorphisms 
in HIV-1 infected patients receiving HAART and the results showed that successful treatment 
was associated with heterozygosity for the CCR5-32, underscoring that the chemokine 
receptor polymorphisms have a modifying effect on the virological response to HAART. The 
course of mean viral load was significantly worse for patients without the CCR5-32 allele and 
the multivariate analysis demonstrated that heterozygosity for the CCR5-32 variant is an 
independent prognostic factor for treatment outcome (Bogner et al., 2004). 
The frequency of the CXCL12- 3'A, CCR2-64I, CCR5-32, and CCR5-Promoter-59029-A/G 
polymorphisms was also evaluated in 155 Brazilian HIV-1 infected on pre and post-HAART 
and their influence on CD4+ T cell counts. The results showed that the CD4+ T cell gain was 
influenced by carriage of one or more of these polymorphisms, highlighting the possibility 
that these genetic traits can be useful to identify patients at risk for faster progression to 
AIDS or therapeutic failure (Rigatto et al., 2008). 
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The chemokine polymorphisms CXCR6-3E/K, In1.1T/C, H7 haplotype, CX3CR1-V249I, and 
CX3CR1-T280M have been shown to affect the course of HIV-1 infection. The influence on 
immunologic and virologic response to HAART in a group of 143 HIV-1 patients was 
studied by Passam et al. (2007). The results revealed an improved immunologic response to 
HAART in patients with the CX3CR1-249I or CX3CR1-280M allele. On the contrary, patients 
with initial viral load suppression due to HAART showed a faster virologic failure in the 
presence of the CXCR6-3K allele. The In1.1T/C polymorphism and H7 haplotype did not 
reveal any specific effect on HAART response. 
7. Conclusion 
So far, the CCR5-32 allele remains the most important host factor known to be associated 
to the resistance to the HIV-1 infection. However, high frequencies of CCR5-32, CCR2-64I, 
and CXCL12-3’A alleles could be all the aftermath or adaptive episodes in which a pathogen 
exerted selective pressure favoring the survival of persons with these beneficial alleles. 
Taken together, the reviewed studies suggest that the existence of genetic polymorphisms 
must be taken into account in the virological and immunological follow-up of HIV-1 
infected patients under treatment with HAART, and that pharmacogenetics is very likely to 
influence the future individualization of HAART. The individual genetic conditions could 
be of interest not only in terms of disease progression, but also on the drug metabolism, and 
therapy response. The identification of genetic polymorphisms in the HIV-1 infected 
individuals could be useful to identify a possible genotype or genotype associations that 
could serve as a marker of either the disease progression in HIV-1 infected individuals or of 
a higher probability of HAART failure. 
Genetic markers could also be useful to better characterize the genetic epidemiology of HIV-
1 infection and to detect individuals at high risk of a faster disease progression. This 
information could lead to the use of different or more aggressive therapeutic strategies, the 
monitoring in shorter interval of time, or both procedures. Most of the studies reviewed 
here signaled that the chemokine receptor antagonists are important new antiviral drugs to 
combat the HIV-1 infection. HIV-1 infected patients in the advanced stages of the disease 
and/or with multiresistance to the antiretroviral agents currently available could benefit 
from these new therapeutic strategies. 
It is possible that a multifaceted approach to antiretroviral therapy, which takes into 
account the genetic host factors and the use of combinations of inhibitors that target 
different steps of the viral life cycle, has the best potential for long-term control of HIV-1 
infection. Such approach could lead to the optimal therapeutic effects of reducing viral 
loads and some immune restoration response, and also to an increase in the span of life of 
infected individuals. In this post-genomic era, the study of host factors and their genetic 
contribution to HIV-1 infection, addresses fundamental issues in our understanding of the 
pathogenesis of the infection and opens new opportunities for therapeutic intervention to 
be developed. 
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